Characteristics and clinical outcomes of patients receiving VSTs for viral prophylaxis
| Patient ID . | Age at first infusion (y) . | Diagnosis . | BMT type . | Indication for VSTs . | VST donor (donor/patient serostatus) . | Target viruses . | Day of infusion (post BMT) . | Virus status at time of infusion . | Viral treatment (completed before VSTs) . | VST dose . | Virus outcome (days post VST) . | Adverse events . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 16.55 | HbSS | MSD | History of CMV and EBV viremia, BK cystitis | HSCT donor CMV: −/+ | EBV, CMV, adenovirus | Day +111 | CMV, EBV, BKV undetectable | (Rituximab, cidofovir, valganciclovir) | 2 × 107/m2 | Sustained remission Last follow-up: 210 d | Acute grade 1 skin GVHD, resolved with topical steroids |
| 6 | 15.93 | HbSS | 8/8 MUD (2nd transplant) | Prophylaxis (history of EBV-PTLD after 1st transplant) | HSCT donor CMV: +/− EBV: +/+ | EBV, CMV, adenovirus | Day +39 | EBV undetectable | (Rituximab before 2nd transplant) | 2 × 107/m2 | Remains virus-free Last follow-up: 225 d | Chronic GVHD (skin) |
| 8 | 13.29 | HbSB0Thal | Haplo | Prophylaxis (donor EBV positive) | HSCT donor (EBV positive) CMV: −/− EBV: +/− | EBV | Day +114 | EBV undetectable | (Rituximab before transplant) | 2 × 107/m2 div into 2 doses | Remains virus-free Last follow-up: 713 d | Acute grade 3-4 skin GVHD responsive to systemic steroids. Later developed chronic skin GVHD |
| 9 | 3.96 | HbSS | 5/6 UCBT | History of adenoviremia | HSCT donor CMV: NA/− ADV: NA/+ | EBV, CMV, adenovirus | Day +118 | Adenovirus undetectable | (Cidofovir, immunoglobulin) | 1 × 107/m2 | Adenovirus relapsed disease 5 months post-VST Intermittent adenovirus reactivation below quantifiable levels <200 copies/mL and positive BAL treated with brincidofovir 5 months post-VST EBV, CMV negative Last follow-up: 399 d | Acute grade 2 skin GVHD, persisted with topical steroids developed into severe chronic skin GVHD resolved with tacrolimus, ECP |
| 10 | 13.38 | HbSS | Haplo | Prophylaxis (Donor EBV positive) | HSCT donor CMV: −/− EBV: +/− | EBV, CMV, adenovirus, HHV6, HPIV3, BKV | Day +80 | Undetectable | (Rituximab before transplant) | 1 × 107/m2 | Remains virus-free Last follow-up: 257 d | None |
| 12 | 18.5 | HbSS | Haplo (PBSCT) | Prophylaxis (Donor EBV, CMV positive) | HSCT donor CMV: +/− EBV: +/− | EBV, CMV, adenovirus, HHV6, HPIV3, BKV | Day +98 | Undetectable | (Rituximab before transplant) | 2 × 107/m2 | Remains virus-free Last follow-up: 180 d | None |
| 13 | 0.95 | WAS and HbSS | Haplo (PBSCT) | History of adenovirus before transplant, prophylaxis (donor EBV positive) | HSCT donor CMV: −/+ EBV: +/+ | EBV, CMV, adenovirus, HHV6, HPIV3, BKV | Day +149 | Undetectable | (Rituximab day +1 after transplant, Cidofovir before transplant) | 5 × 107/m2 | Remains virus-free Last follow-up: 202 d | None |
| Patient ID . | Age at first infusion (y) . | Diagnosis . | BMT type . | Indication for VSTs . | VST donor (donor/patient serostatus) . | Target viruses . | Day of infusion (post BMT) . | Virus status at time of infusion . | Viral treatment (completed before VSTs) . | VST dose . | Virus outcome (days post VST) . | Adverse events . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 16.55 | HbSS | MSD | History of CMV and EBV viremia, BK cystitis | HSCT donor CMV: −/+ | EBV, CMV, adenovirus | Day +111 | CMV, EBV, BKV undetectable | (Rituximab, cidofovir, valganciclovir) | 2 × 107/m2 | Sustained remission Last follow-up: 210 d | Acute grade 1 skin GVHD, resolved with topical steroids |
| 6 | 15.93 | HbSS | 8/8 MUD (2nd transplant) | Prophylaxis (history of EBV-PTLD after 1st transplant) | HSCT donor CMV: +/− EBV: +/+ | EBV, CMV, adenovirus | Day +39 | EBV undetectable | (Rituximab before 2nd transplant) | 2 × 107/m2 | Remains virus-free Last follow-up: 225 d | Chronic GVHD (skin) |
| 8 | 13.29 | HbSB0Thal | Haplo | Prophylaxis (donor EBV positive) | HSCT donor (EBV positive) CMV: −/− EBV: +/− | EBV | Day +114 | EBV undetectable | (Rituximab before transplant) | 2 × 107/m2 div into 2 doses | Remains virus-free Last follow-up: 713 d | Acute grade 3-4 skin GVHD responsive to systemic steroids. Later developed chronic skin GVHD |
| 9 | 3.96 | HbSS | 5/6 UCBT | History of adenoviremia | HSCT donor CMV: NA/− ADV: NA/+ | EBV, CMV, adenovirus | Day +118 | Adenovirus undetectable | (Cidofovir, immunoglobulin) | 1 × 107/m2 | Adenovirus relapsed disease 5 months post-VST Intermittent adenovirus reactivation below quantifiable levels <200 copies/mL and positive BAL treated with brincidofovir 5 months post-VST EBV, CMV negative Last follow-up: 399 d | Acute grade 2 skin GVHD, persisted with topical steroids developed into severe chronic skin GVHD resolved with tacrolimus, ECP |
| 10 | 13.38 | HbSS | Haplo | Prophylaxis (Donor EBV positive) | HSCT donor CMV: −/− EBV: +/− | EBV, CMV, adenovirus, HHV6, HPIV3, BKV | Day +80 | Undetectable | (Rituximab before transplant) | 1 × 107/m2 | Remains virus-free Last follow-up: 257 d | None |
| 12 | 18.5 | HbSS | Haplo (PBSCT) | Prophylaxis (Donor EBV, CMV positive) | HSCT donor CMV: +/− EBV: +/− | EBV, CMV, adenovirus, HHV6, HPIV3, BKV | Day +98 | Undetectable | (Rituximab before transplant) | 2 × 107/m2 | Remains virus-free Last follow-up: 180 d | None |
| 13 | 0.95 | WAS and HbSS | Haplo (PBSCT) | History of adenovirus before transplant, prophylaxis (donor EBV positive) | HSCT donor CMV: −/+ EBV: +/+ | EBV, CMV, adenovirus, HHV6, HPIV3, BKV | Day +149 | Undetectable | (Rituximab day +1 after transplant, Cidofovir before transplant) | 5 × 107/m2 | Remains virus-free Last follow-up: 202 d | None |
Viruses in bold indicate product specificity for this target virus.
BAL, bronchoalveolar lavage; CR, complete remission; Haplo, haploidentical HLA match; PBSCT, peripheral blood stem cell transplant; UCBT, umbilical cord blood transplant; WAS, Wiskott-Aldrich Syndrome.